- Home
- CPRX vs XENE Comparison
CPRX vs XENE Comparison
Compare CPRX & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRX | XENE |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2006 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CPRX | XENE |
|---|---|---|
| Price | $29.20 | $54.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $35.00 | ★ $67.17 |
| AVG Volume (30 Days) | ★ 1.3M | 797.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.24 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $119,072,803.00 | $311,000.00 |
| Revenue This Year | $9.20 | N/A |
| Revenue Next Year | $10.51 | $2,496.48 |
| P/E Ratio | $16.29 | ★ N/A |
| Revenue Growth | ★ 16.39 | N/A |
| 52 Week Low | $19.05 | $28.19 |
| 52 Week High | $28.10 | $62.91 |
Technical Indicators
Market Signals| Indicator | CPRX | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 74.05 | 45.59 |
| Support Level | $22.41 | $52.55 |
| Resistance Level | N/A | $56.66 |
| Average True Range (ATR) | 1.11 | 1.70 |
| MACD | 0.29 | -0.77 |
| Stochastic Oscillator | 57.37 | 8.37 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.